Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS

Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.